HCW Biologics 2026 shareholder vote results

HCW Biologics Inc. reported the results of its 2026 Annual Meeting of Stockholders.

Rhea-AI Filing Summary

HCW Biologics Inc. reported the results of its 2026 Annual Meeting of Stockholders. Stockholders voted on five proposals, including the election of two directors. Lisa M. Giles received 1,127,580 votes for and 230,984 withheld, with 1,189,957 broker non-votes. Rick S. Greene received 1,128,039 votes for and 230,525 withheld, with the same broker non-votes. Four additional proposals each received more votes for than against, with for votes ranging from about 1.08 million to 2.54 million, indicating generally supportive voting outcomes.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Votes for Lisa M. Giles: 1,127,580 votes Votes for Rick S. Greene: 1,128,039 votes Broker non-votes for director election: 1,189,957 votes +3 more

6 metrics

Votes for Lisa M. Giles 1,127,580 votes Election of director at 2026 Annual Meeting

Votes for Rick S. Greene 1,128,039 votes Election of director at 2026 Annual Meeting

Broker non-votes for director election 1,189,957 votes Broker non-votes on each director nominee

Proposal votes high support 2,536,919 for; 1,748 against; 9,854 abstain One non-director proposal at 2026 Annual Meeting

Additional proposal votes 2,231,771 for; 258,125 against; 58,625 abstain Another non-director proposal

Proposal with broker non-votes 1,102,910 for; 233,136 against; 22,518 abstain; 1,189,957 broker non-votes Non-director proposal with broker non-votes

Key Terms

Annual Meeting of Stockholders, Broker Non-Votes, Emerging growth company

3 terms

Annual Meeting of Stockholders financial

"On June 15, 2026, HCW Biologics Inc. ... held its 2026 Annual Meeting of Stockholders"

Broker Non-Votes financial

"Nominee | For | Withheld | Broker Non-Votes ... 1,189,957"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

Emerging growth company regulatory

"Rule 12b-2 of the Securities Exchange Act of 1934 ... Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did HCW Biologics (HCWB) report from its 2026 annual meeting?

HCW Biologics reported voting results from its 2026 Annual Meeting of Stockholders. Shareholders voted on five proposals, including electing two directors and four additional matters, with each proposal receiving more votes for than against based on the disclosed tallies.

Which directors were elected at HCW Biologics' 2026 annual meeting?

Stockholders elected Lisa M. Giles and Rick S. Greene as directors. Giles received 1,127,580 votes for and 230,984 withheld, while Greene received 1,128,039 votes for and 230,525 withheld, with 1,189,957 broker non-votes recorded for each nominee.

How strong was shareholder support for HCW Biologics' 2026 director nominees?

Both HCW Biologics director nominees received substantially more votes for than withheld. Each candidate exceeded 1.12 million votes for, compared with about 231,000 withheld, alongside 1,189,957 broker non-votes, indicating a clear preference among voting shareholders for their election.

How many proposals did HCW Biologics (HCWB) shareholders vote on in 2026?

Shareholders voted on five proposals at the 2026 Annual Meeting. These included electing two directors and four additional proposals, each of which received more votes for than against, with for votes on non-director items ranging from approximately 1.08 million to 2.54 million.

What were the vote totals on HCW Biologics' non-director proposals in 2026?

Four non-director proposals showed favorable tallies. One received 2,536,919 votes for, 1,748 against, 9,854 abstain; another 2,231,771 for, 258,125 against, 58,625 abstain; another 1,102,910 for, 233,136 against; and another 1,083,864 for, 251,605 against, each with 1,189,957 broker non-votes where shown.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 04:30 PM Learn about SEC filing dates

false 0001828673 0001828673 2026-06-15 2026-06-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 15, 2026

HCW Biologics Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware	001-40591	82-5024477
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2929 N. Commerce Parkway
Miramar, Florida		33025
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 954 842-2024

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		HCWB		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 15, 2026, HCW Biologics Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders voted on the following five proposals and cast their votes as follows:

1. The Company’s stockholders elected the persons listed below as Class II directors listed in the accompanying proxy statement to serve a three-year term expiring at the 2029 annual meeting of stockholders and until such director’s successor is duly elected and qualified or until such director’s earlier death, resignation, disqualification or removal.

Nominee		For			Withheld			Broker Non-Votes
Lisa M. Giles		1,127,580			230,984			1,189,957
Rick S. Greene		1,128,039			230,525			1,189,957

2. The Company’s stockholders ratified the appointment of Crowe LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026.

For		Against		Abstain		Broker Non-Votes
2,536,919		1,748		9,854		—

3. The Company’s stockholders approved an amendment to the Company’s certificate of incorporation on or before the one (1) year anniversary of the Annual Meeting, to implement one or more reverse stock splits of the outstanding shares of the Company’s common stock, par value $0.0001 per share (our “Common Stock”) (as necessary to maintain a listing of our Common Stock on The Nasdaq Stock Market LLC (“Nasdaq”)) in an aggregate range from one-for-five (1:5) up to one-for-twenty (1:20).

For		Against		Abstain		Broker Non-Votes
2,231,771		258,125		58,625		—

4. The Company’s stockholders approved, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of our Common Stock upon exercise of up to 2,477,292 Common Stock Purchase Warrants (the “Common Warrants”) issued pursuant to that certain Securities Purchase Agreement, dated February 17, 2026, entered into in connection with the Company’s follow-on public offering of Units, consisting of one share of Common Stock purchased for $0.6055 and one Common Warrant which may be exercised to purchase one share of Common Stock for $0.6055 per share..

For		Against		Abstain		Broker Non-Votes
1,102,910		233,136		22,518		1,189,957

5. The Company’s stockholders approved, for purposes of complying with Nasdaq Listing Rule 5635(d), the repricing of certain warrants issued on November 20, 2025 to purchase up to 3,020,410 shares of our Common Stock pursuant to that certain Existing Warrants Amendment Agreement, dated February 17, 2026, to reduce the exercise price of the Existing Warrants to $0.6055 per share, and to approve the issuance of shares of our Common Stock upon exercise of the Existing Warrants as so amended.

For		Against		Abstain		Broker Non-Votes
1,083,864		251,605		23,095		1,189,957

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	HCW BIOLOGICS INC.
Date: June 15, 2026	By:	/s/ Hing C. Wong
		Hing C. Wong, Founder and Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.0 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.9 KB